Carcinoma of duodenum

Summary

Carcinoma of duodenum (MONDO:0021335) is a cancer and 24 clinical trials. Top therapeutic interventions include dalteparin sodium, obeticholic acid, and pantoprazole. A subtype of duodenum cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma of duodenum
Mondo ID	MONDO:0021335
ICD-11	220022932
NCIT	C4803
SNOMED CT	254570009
UMLS	C0541912
MedGen	107442
GARD	0025314
Anatomy (UBERON)	UBERON:0002114
Is cancer (heuristic)	yes

Also known as: cancer of duodenum · cancer of the duodenum · carcinoma of duodenum · carcinoma of the duodenum · duodenal cancer · duodenal carcinoma · duodenum carcinoma

Disease family

This is a subtype of duodenum cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal neoplasm › small intestine neoplasm › small intestine cancer › duodenum cancer › carcinoma of duodenum

Related subtypes (1): ampulla of vater cancer

Subtypes (2): duodenal adenocarcinoma, carcinoma of the ampulla of vater

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	16
PHASE2	4
PHASE4	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07262957	PHASE4	RECRUITING	Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
NCT01642875	PHASE4	UNKNOWN	Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy
NCT07155525	PHASE3	RECRUITING	Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
NCT03139487	PHASE2	UNKNOWN	A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
NCT05223036	PHASE2	TERMINATED	Testing Obeticholic Acid for Familial Adenomatous Polyposis
NCT05251233	PHASE2	TERMINATED	Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
NCT05641233	PHASE1/PHASE2	UNKNOWN	Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
NCT06690281	PHASE2	WITHDRAWN	A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
NCT02012699	Not specified	RECRUITING	Integrated Cancer Repository for Cancer Research
NCT03631173	Not specified	ACTIVE_NOT_RECRUITING	Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy
NCT06414122	Not specified	NOT_YET_RECRUITING	Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
NCT06453590	Not specified	ACTIVE_NOT_RECRUITING	Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
NCT00628186	Not specified	COMPLETED	Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy
NCT00639314	Not specified	COMPLETED	Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
NCT01438385	Not specified	UNKNOWN	Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
NCT01661049	Not specified	COMPLETED	Duodenal Cancer - Retrospective Analysis
NCT01838109	Not specified	COMPLETED	Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery
NCT02446379	Not specified	WITHDRAWN	Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery
NCT02954302	Not specified	UNKNOWN	Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy
NCT03150615	Not specified	COMPLETED	Enteral Nutrition After Pancreaticoduodenectomy
NCT03346980	Not specified	COMPLETED	Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)
NCT03525067	Not specified	COMPLETED	Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies
NCT04104230	Not specified	UNKNOWN	Quebec Pancreas Cancer Study
NCT05134961	Not specified	COMPLETED	Long-term Outcomes After Resection of Primary Duodenal Adenocarcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DALTEPARIN SODIUM	4	1
OBETICHOLIC ACID	4	1
PANTOPRAZOLE	4	1
RIVAROXABAN	4	1
CHEMBL4303680	0	1
CHEMBL5197244	0	1
CHEMBL5412701	0	1